Non‐metastatic muscle‐invasive bladder cancer: the role of age in receiving treatment with curative intent
Authors:
- Lisa M.C. van HoogstratenLHLisa M.C. van Hoogstraten
- Theodora M. RippingTRTheodora M. Ripping
- BlaZIB study groupBGBlaZIB study group
Open Access
- 8 February 2022
- journal article
- research article
- Published by Wiley in BJU International
- Vol. 130 (6) , 764-775
Abstract
Objectives: To evaluate which patient and tumour characteristics are associated with remaining untreated in patients with potentially curable, non‐metastatic muscle‐invasive bladder cancer (MIBC), and to compare survival of untreated vs treated patients with similar characteristics. Patients and methods: For this cohort study, 15 047 patients diagnosed with cT2–T4aN0/xM0/x urothelial MIBC between 2005 and 2019 were identified in the Netherlands Cancer Registry. Factors associated with remaining untreated were identified using logistic regression analyses. Interhospital variation was assessed using multilevel analysis. Using a propensity score, the median overall survival (mOS) of untreated and treated patients was evaluated. Analyses were stratified by age (<75 vs ≥75 years). Results: One‐third of patients aged ≥75 years remained untreated; increasing age, worse performance status, worse renal function, cT4a stage and previous radiotherapy in the abdomen/pelvic area increased the odds of remaining untreated. One in 10 patients aged <75 years remained untreated; significant associations were only found for performance status, renal function and cT4a stage. Interhospital variation for remaining untreated was largest for patients aged ≥75 years, ranging from 37% to 69% (case‐mix‐adjusted). Irrespective of age, mOS was significantly worse for untreated patients: 6.4 months (95% confidence interval [CI] 5.1–7.3) vs 16.0 months (95% CI 13.5–19.1) for treated patients. Conclusion: On average, one in five patients with non‐metastatic MIBC remained untreated. Untreated patients were generally older and had a more unfavourable prognostic profile. Untreated patients had significantly worse overall survival, regardless of age. Age alone should therefore not affect treatment decision‐making. Considering the large interhospital variation, a proportion of untreated patients might be wrongfully denied life‐prolonging treatment.Keywords
Funding Information
- KWF Kankerbestrijding (IKNL 2015‐7914)
- KWF Kankerbestrijding
This publication has 31 references indexed in Scilit:
- Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic ReviewEuropean Urology, 2014
- Challenging treatment decision-making in older urologic cancer patientsWorld Journal of Urology, 2013
- Use of Potentially Curative Therapies for Muscle-invasive Bladder Cancer in the United States: Results from the National Cancer Data BaseEuropean Urology, 2013
- Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patientsBritish Journal of Cancer, 2013
- Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder CancerNew England Journal of Medicine, 2012
- Long-Term Outcomes of Selective Bladder Preservation by Combined-Modality Therapy for Invasive Bladder Cancer: The MGH ExperienceEuropean Urology, 2012
- Feasibility of Radical Transurethral Resection as Monotherapy for Selected Patients With Muscle Invasive Bladder CancerJournal of Urology, 2010
- Treatment and outcome in muscle invasive bladder cancer: a population-based surveyWorld Journal of Urology, 2010
- Age‐adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancerCancer, 2008
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987